Methods and Results. Using platelet-rich plasma (PRP), we found that SK (5,000 units/ml) but not urokinase (2,500 units/ml) or recombinant tissue-type plasminogen activator (2,500 units/ml) caused platelet aggregation in PRP from 14 of 100 normal volunteers. In 13 consecutive patients treated with SK for acute myocardial infarction, SK-mediated platelet aggregation was induced in five patients within 1 week after treatment. SK-mediated platelet aggregation was associated with significantly increased titers of both anti-SK antibodies and SK-neutralizing activity in plasma; it was partially inhibited by aspirin (1 mM) and by aprotinin (500 kallikrein inhibitor units/ml) and completely inhibited by tranexamic acid (1 mM) and by prostaglandin E1 (9 ,M) . Addition of SK (1,000 or 5,000 units/ml) induce a statistically significant dose-dependent thromboxane B2 release in mixtures of PRP with plasma from subjects with SK-induced aggregation but not in samples of PRP mixed with plasma from nonresponders; addition of recombinant tissue-type plasminogen (1 50 jug/ml) did induce thromboxane B2 release. Mixing experiments with PRP and immunoglobulin G from reactive and nonreactive donors revealed that SK-induced aggregation requires the presence of anti-SK antibodies. When 1251-SK (50 nM) was used, platelets preincubated with plasminogen (0.5 ,uM) bound 9,500±600 (mean±SEM, n=6) molecules SK/platelet, which increased to 25,000±3,100 molecules/platelet after thrombin stimulation.
Tranexamic acid (1 mM) blocked specific binding of SK to resting platelets.
Concluions. These data demonstrate that SK-induced platelet aggregation is initiated by the binding of anti-SK antibodies to the SK-plasminogen complex located on the platelet surface. SK-induced platelet activation may limit the therapeutic effectiveness of the drug, and in view of the high prevalence of aggregation in a normal population, prospective evaluation of the effects of platelet aggregation during treatment with SK is warranted. (Circulation 1991; 84:84-91) Streptokinase (SK) is one of the plasminogen activators currently available for therapeutic use, but it is derived from nonhuman sources.1 Exposure to SK induces specific antibody formation2 and provokes allergic responses in up to 5% of patients receiving SK.3 SK has been reported to induce thromboxane A2 synthesis and platelet activation when administered to patients with acute myocardial infarction,4 and it may initiate platelet aggregation by a Supported by a grant from the Geconcerteerde Onderzoeksacties (Project 85-90/78). D.E.V. is the recipient of a Clinician-mechanism involving specific anti-SK antibodies.5 Theoretically, platelet activation brought about by SK may limit the therapeutic effectiveness of the drug and may contribute to the pathogenesis of early reocclusion. 6 In experimental studies, inhibition of platelet function has been shown to enhance the thrombolytic response to SK7 and to prevent reocclusion. 8 The present study was designed to 1) define the prevalence of SK-mediated platelet aggregation in a control population and in a population after SK infusion, 2) correlate platelet aggregation with an-immunosorbent assay (ELISA) plates and for quantitative binding studies; Kabikinase from Kabi Diagnostica, Stockholm, Sweden; and Streptase from Hoechst Pharmaceuticals, Brussels. These three SK preparations were used interchangeably for platelet aggregation studies. Recombinant tissue-type plasminogen activator (rt-PA, Actilyse) was provided by Boehringer Ingelheim, Ingelheim, FRG.; urokinase (Abbokinase) was purchased from Abbott Pharmaceuticals, Chicago, Ill., and acylated plasminogen-SK activator complex (APSAC, Eminase) was purchased from Beecham Pharmaceuticals, Brussels. Tranexamic acid (Exacyl) was from Laboratoires Choay, Paris; 6-aminohexanoic acid (6-AHA) was To determine the prevalence of SK-induced platelet aggregation in the normal population, fresh PRP from each of the 100 volunteers was used. Platelet aggregation was monitored at 37°C with stirring using a dual-chamber aggregometer'2 after the addition of SK (1,000, 5,000, or 10,000 units/ml), urokinase (5,000 units/ml), or rt-PA (2,500 units/ml) to 250 ,l PRP. In four individuals with SK-induced aggregation, platelet aggregation was also measured after the addition of 0.14 units APSAC. The SK, urokinase, and APSAC units indicated on the labels were used, and rt-PA was converted from the weight indicated on the label to units, assuming a specific activity of 500,000 units/mg. The effect of aprotinin (500 units/ ml), PGE1 (9 ,uM) , tranexamic acid (1 mM), or 6-AHA (1 mM) on SK-induced platelet aggregation was studied using PRP from reactive donors. The inhibitors were added to PRP 2 minutes before the addition of SK (5,000 units/ml).
The secretion of adenosine triphosphate (ATP) during platelet aggregation was monitored using the firefly luminescence method13 in a Lumiaggregometer (Chrono-Log Corp., Havertown, Pa.). For the measurement of thromboxane B2, samples of PRP from nonresponsive donors were mixed 1:1 with plasma from previously identified donors that either supported platelet aggregation (responders) or that did not support platelet aggregation (nonresponders) after the addition of SK (5,000 units/ml) to PRP. SK or tissuetype plasminogen activator (t-PA) was added to the platelet suspensions, incubated for 4 minutes at 37°C
with stirring, and then centrifuged at 10,000w for 3 minutes. The amount of thromboxane B2 in the plasma supernatant was measured by a standard radioimmunoassay as previously described. '4 Titration ofAnti-SK Antibodies and SK Neutralizing Activity Antibody titers to SK in plasma were measured using a one-site noncompetitive ELISA according to the method of Engvall and Perlman.'5 Wells of micro-ELISA plates were incubated with a 200-gl solution of albumin-free SK (1,000 units/ml) in phosphate buffered saline (PBS) for 24 hours at 4°C. The wells were then treated with PBS containing 1% bovine serum albumin and washed three times with PBS containing 0.002% Tween 80 (PBS-Tween).
Plasma (100 pul) in appropriate twofold dilutions was added to the wells and incubated for 2 hours at room temperature. The wells were again washed three times with PBS-Tween and incubated for 1 hour with the horseradish peroxidase-conjugated goat IgG raised against human IgG. After three additional washes with PBS-Tween, the peroxidase reaction was performed by addition of 200 ug/ml o-phenylenediamine and 0.003% hydrogen peroxide in 0. 
Prevalence of SK-Induced Platelet Aggregation
Venous blood was collected from 100 normal volunteers, and PRP was generated as described above. All of the subjects were healthy blood donors, and none had previously received SK. Forty-one percent of the donors were women, and the age of the donors was 39±13 (mean±SD) years. Fourteen of the samples tested showed a pronounced platelet aggregation response after the addition of SK to PRP to a final concentration of 5,000 units/ml (Table 1 ). There were nine men and five women in this group, with an age distribution of 35 ± 12 years. None of these 14 samples of PRP aggregated with 1,000 units SK/ml, whereas only eight of 14 aggregated with 10,000 units SK/mI. Urokinase and rt-PA did not initiate platelet aggregation in any sample. APSAC also initiated platelet aggregation in PRP from four of four (100%) selected individuals with an aggregatory response to SK. Fifteen individuals were retested between 2 weeks and 2 months after their first screening; 10 individuals tested negative on both occasions, and five individuals tested positive on both occasions. The frequency distribution of anti-SK antibody titer and SK-neutralizing activity is depicted in Figures 1A and 1B, respectively. Platelet aggregation was observed in 13 of 34 subjects with a titer of 0.8 units/ml or more and in one of 66 with a titer of less than 0.8 units/ml (p<0.001). The median titer in the subjects with aggregation was 13 units/ml; in the subjects without agregation, it was 0.4 units/ml. Platelet aggregation occurred in 12 of 28 subjects with a SK-neutralizing activity of more than 10 units/ml and in two of 72 subjects with SK-neutralizing activity of less than 10 units/ml (p<0.001). Linear regression analysis of the SK-neutralizing activity versus the anti-SK antibody titers yielded a correlation coefficient of 0.7. Table 2 summarizes the antibody titers for the group divided on the basis of the aggregatory response to SK in vitro. Both anti-SK antibody titers and SK neutralizing activity were significantly higher in the subjects with SK-induced platelet aggregation than in the nonresponsive group.
Venous blood samples were also obtained from 13 patients before and 1 week after treatment with SK for acute myocardial infarction. Platelet aggregation induced with 5,000 units SK was measured using either PRP from the individual patients or by adding Mechanism of SK-Induced Platelet Aggregation SK-induced platelet aggregation was accompanied by ATP secretion, which is indicative of platelet activation and secretion (Figure 2 ). Thromboxane B2 levels were measured in plasma after the addition of SK to samples of plasma from five positive and five negative donors mixed 1:1 with fresh PRP from a known nonreactive donor to final concentrations of 100, 1,000, or 5,000 units/ml and after the addition of rt-PA to a final concentration of 1 or 50 ,ug/ml (Table  3) . rt-PA did not cause a significant release of thromboxane B2, whereas SK induced a concentration-dependent release of thromboxane B2. In the responders, a significant thromboxane B2 release was observed after the addition of 1,000 units/ml SK, a concentration that did not cause visible platelet aggregation.
The effects of inhibitors of fibrinolysis or of platelet function on platelet aggregation induced with 5,000 units SK/mi are summarized in Table 4 . Tranexamic acid (1 mM), 6-AHA (1 mM), and PGE1 (9 /LM) completely abolished SK-induced aggregation, whereas aprotinin (500 kallikrein inhibitor units/mi) and aspirin (1 mM) only partially inhibited SKinduced aggregation. Figure 3 illustrates the dependence of SK-induced platelet aggregation on specific IgG. Aggregation was monitored after the addition of 5,000 units/ml SK to PRP preincubated with serum or purified IgG from Discussion Anti-SK antibodies and SK-neutralizing activity in plasma are ubiquitous in the adult population and increase in titer after infection with ,B-hemolytic streptococci or treatment with SK.18-20 This widespread occurrence has played a role in determining the therapeutic dose of SK19 and in the generalized use of adjunctive therapy with steroids. We5 previously reported a specific instance in which SK-specific antibodies supported platelet aggregation in vitro and were circumstantially related to an episode of clot propagation during intracoronary infusion of SK.
In the p:-sent study, we found a relatively high prevalence of SK-induced platelet aggregation in PRP from a normal population of healthy blood donors (14% with 5,000 units/ml SK). A highly significant statistical correlation was found between this in vitro aggregatory response and the anti-SK antibody titer, measured either by SK-neutralizing activity or by ELISA techniques. In some instances, however, a high titer of anti-SK antibodies did not correspond with in vitro aggregation to SK, suggest- 
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Values are mean-+SD. n, Number of plasma samples tested; SK, streptokinase; rt-PA, recombinant tissue-type plasminogen activator. In the responders, platelet aggregation was inducible in all samples after addition of 5,000 units/ml SK to mixtures of platelet-rich plasma with plasma from donors with SK-induced platelet aggregation. *p<0.05 and tp<0.02 vs. baseline values for each group. Values are mean±SEM. n, Number of donors tested; SK, streptokinase; KIU, kallikrein inhibitor units; 6-AHA, 6-aminohexanoic acid; PGE1, prostaglandin E1. Compounds were incubated with platelet-rich plasma for 2 minutes before addition of 5,000 units/ml SK except for aspirin, which was incubated for 30 minutes at 37°C. Percent inhibition was determined by comparisons with platelet-rich plasma from the same donor used on the same day. All experiments were performed in duplicate.
ing that the platelet aggregating antibodies constitute a distinct qualitative subset of anti-SK antibodies.
Platelet aggregation was not observed with urokinase or rt-PA but did occur with APSAC, which contains immunoreactive SK. 21 These observations indicate that SK-induced platelet aggregation is specific for SK and not dependent on the conversion of plasminogen to plasmin. It is important to note that thrombolytic therapy with t-PA and with SK has been associated with platelet activation, as evidenced by increased thromboxane B2 production4,22 through an undefined mechanism, and hyperplasminemia itself23 has been shown to activate platelets and to stimulate thrombin activation,24 which is another potent agonist of platelet activation.
Plasminogen does appear to play a role in SKinduced platelet aggregation, since its introduction in a mixture of platelets, SK, and plasminogen-depleted plasma from a responsive donor promptly led to platelet aggregation. Furthermore, the addition of an inactive plasminogen mutant in an identical experiment also initiated platelet aggregation. However, aprotinin partially inhibited SK-induced platelet ag- gregation, suggesting a role for plasmin activity as well.
Taken together, these findings can be interpreted as indicative of an interaction between two independent mechanisms in promoting platelet aggregation in the presence of SK: the first mechanism is immunologically based and requires plasminogen but not plasmin activity, and the second is related to the more generic platelet-activating effects of plasmin. The role of specific anti-SK antibodies in SKinduced platelet aggregation is supported by mixing experiments using IgG, serum, and platelets. The combination of fresh human platelets from a nonresponsive donor, SK, and serum or IgG isolated from a responsive donor promoted platelet aggregation in vitro, whereas aggregation was not observed in identical experiments in which serum or IgG from a nonresponsive donor was used. Furthermore, in binding experiments using`251-SK, IgG does not appear to be a requirement for, nor does it appear to Whether or not SK-specific platelet aggregatory antibodies promote thromboembolism during treatment with SK or diminish the therapeutic efficacy of the drug is not known. Induction of platelet aggregation in vitro did not occur with 1,000 units/ml SK, whereas it was readily obtained with 5,000 units/ml, which is substantially higher than circulating levels of SK during intravenous administration of 1.5 million units SK for 1 hour. However, in the responsive group, a small but significant release of thromboxane B2 was observed with subaggregatory concentrations of SK (i.e., 1,000 units/ml). These findings suggest that a critical threshold concentration of SK must be present on the platelet surface before antibodyinduced platelet aggregation can efficiently proceed but also that platelet activation occurs to some extent in the absence of overt aggregation. Furthermore, only eight of 14 positive samples aggregated after the addition of an even higher concentration of SK (i.e., 10,000 units/ml), which supports the concept that the ratio of antigen to antibody is also important in determining whether or not aggregation will proceed. When SK is delivered into a thrombosed peripheral or coronary artery, its local concentration may become high enough to induce platelet aggregation. Indeed, the first patient with SK-induced platelet aggregation was identified by clot propagation in a coronary artery coincidental with local infusion of SK.5 0thers12627 have also described a paradoxical occirrence of thrombosis during therapy with SK, whereas Fitzgerald et a14 reported a marked production of thromboxane during treatment with SK. The propensity of SK to activate platelets may play a role in primary resistance and in acute reocclusive phenomena after the administration of SK for acute myocardial infarction. In our studies, aspirin partially attenuated SK-induced platelet aggregation in vitro, which suggests that the additive effect of aspirin and SK with respect to clinical outcome in patients with acute myocardial infarction28 may be due, at least in part, to the effect of aspirin on SK-induced platelet aggregation.
In summary, specific, qualitatively distinct anti-SK antibodies are capable of promoting SK-induced platelet aggregation. This phenomenon occurs after anti-SK antibodies react with SK bound to the platelet surface via plasminogen, which in turn, triggers platelet activation and aggregation. SK-induced platelet aggregation appears to be related to the titer of anti-SK antibodies but in vitro requires the presence of relatively high concentrations of SK. Lower concentrations of SK promote platelet activation and thromboxane production in sensitized individuals, which may be partially mitigated by the simultaneous administration of aspirin. The influence of these antibodies on patient response and outcome during treatment with SK likely merits further investigation.
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